ClinicalTrials.gg
Drug

Defactinib clinical trials

Also written VS-6063 and PF-04554878.

Includes 3 studies of Defactinib hydrochloride.

studies test it
32
open now
12
in phase 3
1
first study started
2008

Counted the way a researcher would: Defactinib with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.

This browser remembers your choice.

How each study uses defactinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the defactinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
8 May 2025 · AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) · NDA 219616 (FDA, Drugs@FDA; as defactinib hydrochloride; in a combination)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Defactinib
24
defactinib (VS-6063)
3

Development codes

VS-6063
12
PF-04554878
5

Studies by the year they started

31 studies that test it; most in 2024 (6); 1 more planned to start later

Studies that test defactinib, by start year
YearStudies
20081
20135
20154
20162
20171
20191
20201
20212
20222
20233
20246
20251
20262

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
14
Phase 2
20
Phase 3
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 11 · Other 21

Verastem, Inc. (11) · Memorial Sloan Kettering Cancer Center (3) · Washington University School of Medicine (3) · National Cancer Institute (NCI) (2) · Emory University (2) · M.D. Anderson Cancer Center (2) · Lei Zheng (1) · Girish Dhall, MD (1)

Often tested with

Tested in the same studies.

RO5126766 (15) · Adavosertib (1) · Afatinib (1) · Binimetinib (1) · Capivasertib (1) · Copanlisib (1) · Copanlisib hydrochloride (1) · Crizotinib (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 4

Studies that test defactinib.

Studies

Open first, then newest update. How each study uses defactinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 32

See all 32 studies that test defactinib →

Given beside what is tested · 3 — defactinib is usual care or a partner of the new treatment

Codes

What other systems call defactinib · ClinicalTrials.gg INT006376

  • MeSH (NLM) C584510defactinibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 53O87HA2QUDEFACTINIBConfirmed FDA, NLM, Wikidata
  • Wikidata Q27077009defactinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C79809DefactinibOne source FDA
  • DrugBank DB12282One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.